Обычные болезни в клинических кохартах - не всегда то, что они выглядят.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rahimov Fedik, Jacobs Benjamin M, Lee John S, Mahi Naim A, Blumenfeld Andrew, Alsheikh Ammar J, Abbasi Ali, Reppell Mark, Pivorunas Valerie L, Sigurðsson Haukur J, Sawcer Stephen, Guay Heath, Waring Jeffrey F, Jacob Howard J, Smaoui Nizar
Аннотация
Оригинал публикации
Common Diseases in Clinical Cohorts - Not Always What They Seem.
BACKGROUND: Misdiagnosis or underdiagnosis of rare diseases in patients with diagnoses of common diseases can lead to delayed or inappropriate treatments, thereby complicating the management of both rare and common conditions. Despite advances in molecular diagnostic techniques, the effect of rare diseases on the diagnosis of common diseases in research and clinical trials has not been comprehensively investigated.
METHODS: We used exome- and genome-sequencing data from participants in the U.K. Biobank, a research study, and five clinical trials involving patients who had received a primary diagnosis of multiple sclerosis, inflammatory bowel disease, or atopic dermatitis to assess the incidence of monogenic rare diseases that often manifest with clinical symptoms overlapping with those of these common diseases.
RESULTS: We identified 153 U.K. Biobank participants who carried a rare variant that contributes to a molecular diagnosis of a monogenic disorder - 53 of 1850 (2.86%) with a diagnosis of multiple sclerosis, 75 of 6681 (1.12%) with a diagnosis of inflammatory bowel disease, and 25 of 998 (2.50%) with a diagnosis of atopic dermatitis. We replicated the findings regarding such rare disease-causing variants in two independent cohorts - one including patients with a diagnosis of multiple sclerosis, and the other patients with a diagnosis of inflammatory bowel disease - who had undergone genome sequencing for research and for clinical trials, respectively. By combining genome and transcriptome analyses, we showed that molecular diagnosis can potentially elucidate mechanisms of inadequate response to therapeutic intervention.
CONCLUSIONS: Our study shows the value of systematic genome sequencing in understanding the phenotypic heterogeneity of common diseases and identifying failure to diagnose rare diseases and highlights the benefits of deep molecular phenotyping in clinical trials and patient care. (Funded by AbbVie and NIHR Cambridge Biomedical Research Centre.).